Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 exploratory study of romiplostim N01 for chemotherapy-induced thrombocytopenia
ChiCTR2500103447Phase 2Not yet recruiting
- Sponsor
- Suqian First Hospital
- Start
- May 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of romiplostim in chemotherapy-induced thrombocytopenia (CIT), sponsored by Suqian First Hospital. Primary endpoint: Proportion of subjects with effective treatment. Planned start May 2025; status: not yet recruiting.
02
Drugs
romiplostim
03
Conditions
chemotherapy-induced thrombocytopenia (CIT)
Beyond the preview
Go deeper on ChiCTR2500103447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500103447.